The effect of quercetin on oxidative DNA damage and myelosuppression induced by etoposide in bone marrow cells of rats by Papież, Monika
Regular paper
The effect of quercetin on oxidative DNA damage and 
myelosuppression induced by etoposide in bone marrow  
cells of rats*
Monika A. Papież*
Department of Cytobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
There is increasing evidence for the existence of an as-
sociation between the presence of etoposide phenox-
yl radicals and the development of treatment-related 
acute myeloid leukemia (t-AML), which occurs in a few 
percent of patients treated with this chemotherapeutic 
agent. The most common side effect caused by etopo-
side is myelosuppression, which limits the use of this 
effective drug. The goal of the study was to investigate 
the influence of antioxidant querectin on myelosuppres-
sion and oxidative DNA damage caused by etoposide. 
The influence of quercetin and/or etoposide on oxida-
tive DNA damage was investigated in LT-12 cell line and 
bone marrow cells of rats via comet assay. The effect of 
quercetin on myelosuppression induced by etoposide 
was invetsigated by cytological analysis of bone mar-
row smears stained with May-Grünwald-Giemsa stain. 
Etoposide caused a significant increase in oxidative 
DNA damage in bone marrow cells and LT-12 cell line in 
comparison to the appropriate controls. Quercetin sig-
nificantly reduced the oxidative DNA damage caused by 
etoposide both in vitro and in vivo. Quercetin also signifi-
cantly protected against a decrease in the percentage of 
myeloid precursors and erythroid nucleated cells caused 
by etoposide administration in comparison to the group 
treated with etoposide alone. The results of the study in-
dicate that quercetin could be considered a protectively 
acting compound in bone marrow cells during etoposide 
therapy.
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INTRODUCTION
There is evidence of a relationship between oxida-
tive stress and the occurrence of acute myeloid leuke-
mia (Battisti et al., 2008). Oxidative stress coincides with 
an increased frequency of DNA damage, the presence 
of specific mutations and an decrease in antioxidant ca-
pacity in patients with AML (Sallmyr et al., 2008, Zhou 
et al., 2007, Zhou et al., 2010). The use of conventional 
chemotherapeutic agents may increase oxidative stress 
(Kasapović et al., 2010). This phenomenon has a favora-
ble therapeutic effect in cancer cells, because strong oxi-
dative stress can induce apoptosis of these cells (Feng et 
al., 2007). However, oxidative stress may be detrimental 
to normal proliferating cells, such as hematopoietic pro-
genitor cells, and may lead to oxidative damage to mac-
romolecules, including DNA damage.
One of the cytostatic drugs, from which phenoxyl 
radicals are formed in bone marrow cells, is etoposide 
(Haim et al., 1987). These radicals are likely to facilitate 
leukemogenesis, which occurs in a few percent of pa-
tients treated with this drug (Whitlock et al., 1991). They 
are formed in large quantities under the influence of the 
metabolic conversion of etoposide by myeloperoxidase. 
High levels of activity of this enzyme are detected in 
precursors of myeloid lineage (Kagan et al., 1999; Vlas-
ova et al., 2011). It is possible that the development of 
t-AML could be prevented by limiting the amount of 
etoposide phenoxyl radicals.
The second serious side effect caused by etoposide 
is myelosuppression (Kobayashi & Ratain, 1994), which 
limits its application and may be a cause of the failure 
of chemotherapy. Etoposide inhibits proliferation of 
cells in the G2/M phase of the cell cycle (Ishiyama et 
al., 1994). The development of bone marrow hypoplasia 
induced by etoposide could also partially be attributed to 
the pro-oxidant action of its radicals. Oxidation of thiol 
groups by etoposide phenoxyl radicals may lead to a de-
cline in the level of glutathione and increased oxidative 
damage to DNA, which in turn contributes to the for-
mation of DNA strand breaks (Kagan et al., 1999; Sall-
myr et al., 2008). Such extensive damage in bone marrow 
progenitor cells can cause apoptosis or necrosis leading 
to bone marrow hypoplasia.
On the basis of the fact that etoposide side effects 
in bone marrow may correspond to the pro-oxidant ac-
tion of this drug, appropriate antioxidant supplements 
could provide effective protection. One of such natural 
antioxidants are plant polyphenols, e.g. quercetin, which 
scavenging free radicals and chelating transition metal 
ions (Hu et al., 1995) could be effective in reducing toxic 
metabolites of etoposide.
Due to their low toxicity, polyphenols are not likely 
to potentiate the cytotoxic effects of this drug in nor-
mal cells. Moreover, another characteristic of these com-
pounds is their selective cytotoxic activity in cancer cells 
and the lack of any such action or at least only mini-
mal cytotoxicity in normal cells (Shammas et al., 2006; 
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Feng et al., 2007). Limitation of myelosuppression and 
the genotoxic action of etoposide in normal cells could 
enable an increase in etoposide dosages and improve the 
effectiveness of this chemotherapeutic drug. 
Other studies have shown that quercetin may protect 
cells against induced DNA damage (Wilms et al., 2005; 
Kapiszewska et al., 2007). The aim of the present study 
was to determine the influence of quercetin on oxidative 
DNA damage and myelosuppression caused by etopo-
side.
MATERIAL AND METHODS
Chemicals. Quercetin, etoposide, normal and low 
melting point (LMPA) agarose, triton-X-100, ethylenedi-
amine tetraacetc acid disodium salt (EDTA) and forma-
midopyrimidine-DNA glycosylase (Fpg) were acquired 
from Sigma-Aldrich Co. (St. Louis, Missouri, USA). Di-
methyl sulfoxide (DMSO) was from POCH (Poland). 
The medium (RPMI 1640), serum (FBS), phosphate-
buffered saline (PBS) were purchased from PAA (Pasch-
ing, Austria). 
Cell culture and treatment. Brown Norway 
rat promyelocytic leukemia LT12 cell line (a gen-
erous gift from Professor A.C.M. Martens, Utre-
cht) was cultured in RPMI 1640 supplemented with 
10% FCS, without antibiotics. Cells were incubated 
at 37°C in a 5% CO2 and 95% humidified atmos-
phere and kept in the logarithmic growth phase. 
The cells were seeded in 24-well culture plates at a 
density of 0.5 × 106 cells/ml and incubated in the pres-
ence of different concentrations of quercetin (1–20 µM) 
and/or etoposide (5 µM) for 1–24  hours. Compounds 
were dissolved in DMSO in PBS. Final concentrations 
of DMSO did not exceed 1% DMSO/ml in culture me-
dium. Control cells were incubated only in the presence 
of DMSO. The experiment was repeated two times.
Animals. Three-month-old male Brown Norway 
(BN/CrlCmd) rats were obtained from the Animal Cent-
er, Polish Academy of Sciences Medical Research Center 
(Warsaw, Poland). The animals were housed in plastic 
cages and maintained under standard conditions of 22°C 
and 50–60% humidity, with a 12-h light-dark cycle. They 
had free access to water and a synthetic pellet diet with-
out plant polyphenols (Morawski Label Feed, Kcynia, 
Poland). The experiments were performed in accordance 
with legal requirements, under a licence granted by the 
Jagiellonian University Commission of Ethics.
Treatment with quercetin and etoposide. After 
a two-week period of adaptation, the rats were divided 
into four groups of six animals each. Quercetin (with 0.5 
ml of corn oil as a vehicle) was administered via oral 
gavage at a dose of 100 mg/kg b.w. for 14 consecutive 
days. The dose of quercetin was selected based on stud-
ies in which this polyphenol influenced the redox state 
in rat tissues (Choi et al., 2003). Etoposide was adminis-
tered intraperitoneally for 3 consecutive days at a dose of 
50 mg/kg b.w. This method of administration of etopo-
side is similar to treatment regimens used in some can-
cer patients. The amount of etoposide designed for one 
rat was dissolved in 50 μl DMSO and 1.5 ml of sterile 
PBS. The dose of etoposide was selected according to 
studies in which this cytostatic drug caused severe dam-
age to DNA in the bone marrow of mice (Turner et al., 
2001). The last experimental group was pretreated with 
quercetin for 11 days followed by co-administration of 
etoposide for the last 3 days of the experiment. Control 
rats were given vehicles for the investigated compounds.
Isolation of bone marrow cells. The rats were killed 
by cervical dislocation under vetbutal anaesthesia 2 h af-
ter the final quercetin dose and 1 h after the last dose 
of etoposide administration. The right femurs were ex-
cised immediately after euthanasia and smears were 
prepared form bone marrow using a small paintbrush 
moistened with FBS. Bone marrow from the left femurs 
was flushed with 1 ml FBS into a tube precoated with 
EDTA and washed once in PBS (230 × g, 10 min, 4°C). 
Then, the cell suspension was prepared in PBS and used 
in a comet assay. 
Measurements of oxidative DNA damage using 
an alkaline comet assay. The extent of DNA damage 
was determined via alkaline single cell gel electrophoresis 
according to Tice et al. (1991). Briefly, 5 μl of cells in 
PBS was mixed with 75 μl of 0.5% low melting point 
agarose. The mixture was pipetted into slides precoated 
with 0.5% normal melting point agarose, covered with a 
coverglass and put on ice for 5 minutes. Then, the slides 
were incubated in freshly prepared lysis buffer (2.5 M 
NaCl, 100 mM EDTA, 10 mM Tris, pH 10.0 and 1% 
Triton X-100, 10% DMSO) for 24 h at 4°C. Next, the 
slides were washed three times with an enzyme buffer 
(0.04 M of Hepes, 0.1 M of KCL, 0.5 mM of EDTA, 
and 0.2 mg/mL of bovine serum albumin; pH 8.0) and 
incubated in enzyme buffer for 30 minutes at 37°C with 
1 U/slide of Fpg, which cut the oxidized purine bases. 
Control slides were incubated with enzyme buffer only. 
The slides were then placed in a horizontal electropho-
resis tank containing fresh electrophoresis buffer (300 
mM NaOH, 1 mM EDTA, pH 13) and incubated for 40 
min at 4°C. Electrophoresis was conducted for 30 min 
at 0.74 V/cm and 300 mA. The slides were washed with 
Tris/HCL, pH 7.5 and stained with propidium iodide 
(2.5 μg/ml). Comets were analyzed using a fluorescence 
microscope (Olympus CX-40; Olympus, Tokyo, Japan). 
An image system (The Comet Score™ image analysis 
system, TriTek Corporation, Sumerduck, Virginia, USA) 
was used for the measurement of the percentage of 
DNA in the tail of comets. Two slides per rat or well, 
with 100 randomly selected comets per slide, were ana-
lyzed. 
Cytological evaluation of bone marrow. Smears 
were dried, stained using May-Grünwald-Giemsa stain 
and examined by counting approximately 500 cells/slide 
on three slides from each rat using an Olympus CX-40 
microscope (Olympus, Tokyo, Japan). 
Statistical analysis. Values were expressed as means 
± S.E.M. A one-way analysis of variance (p<0.05) and 
Tukey post hoc test were used to determine significant 
differences between control and experimental samples. 
RESULTS
The level of oxidative DNA damage in the LT-12 cell 
line and rat bone marrow cells after treatment with 
quercetin and/or etoposide
Etoposide, at a concentration of 5 µM, increased the 
level of oxidative damage to DNA in the LT-12 cell line 
after 1 and 24 hours of incubation. Pre-incubation with 
quercetin followed by cotreatment with etoposide signifi-
cantly reduced the level of oxidative DNA damage com-
pared to etoposide-only treated cells (Fig. 1). Incubation 
with quercetin alone at a concentration of 1-20 did not 
significantly affect the level of oxidative DNA damage 
(not shown).
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The administration of etoposide to the rats led to a 
significant increase in the level of oxidative DNA dam-
age in the bone marrow cells in comparison to the 
control group. The use of quercetin before and during 
administration of etoposide resulted in a significant de-
crease in the level of oxidative DNA damage compared 
to etoposide alone. Quercetin did not exert a significant 
influence on the level of oxidative DNA damage in bone 
marrow cells compared to the control (Fig. 2).
The influence of quercetin on the cytology of bone 
marrow in rats treated with etoposide
Hypoplasia of the bone marrow was observed in the 
rats treated with etoposide. A significant decrease in 
the percentage of precursors of myeloid lineage, eryth-
roid nucleated cells and a non-significant decrease in the 
percentage of lymphocytes was observed in comparison 
to the control. The predominant leukocytes in the bone 
marrow of rats treated with etoposide were mature gran-
ulocytes (Table 1).
The administration of quercetin before and during 
treatment with etoposide led to a reduction in bone mar-
row hypoplasia. A significant increase in the percentage 
of myeloid precursors (from myeloblast to metamyelo-
cyte stages) and nucleated erythroid cells was observed 
after pre-treatment with quercetin followed by etoposide 
administration compared to etoposide alone. A clear, al-
though non-significant, trend could be observed towards 
an increase in the percentage of lymphocytes in the 
group treated with quercetin and etoposide in compari-
son to the etoposide-only treated group. Quercetin alone 
did not exert any significant impact on the proportion of 
bone marrow cells (Table 1).
DISCUSSION
The likely reason for the leukemogenic action of 
etoposide is DNA damage in the precursor cells of the 
myeloid lineage caused by its phenoxyl radicals. It has 
been proved that a relationship exists between the for-
mation of etoposide phenoxyl radicals and mixed-lineage 
leukemia (MLL) gene rearrangements in patients with t-
AML (Vlasova et al., 2011). Etoposide phenoxyl radicals 
can lead to oxidative DNA damage. One of the highly 
mutagenic oxidative lesions of DNA is 7,8-dihydro-8-ox-
oguanosine (8-OH-dG), elevated levels of which are de-
tected in tumor cells (Irie et al., 2005), indicating its par-
ticipation in carcinogenesis.
It can be assumed that quercetin as an antioxidant 
will scavenge phenoxyl radicals of etoposide and limit 
its pro-oxidant activity in myeloid pregenitor cells. The 
present study indirectly confirms this hypothesis, because 
pre-treatment with quercetin followed by etoposide sig-
nificantly decreased the amount of oxidative damage to 
purine DNA bases induced by this chemotherapeutic 
agent in bone marrow cells of rats and rat myeloid LT12 
cells. These results are consistent with other studies 
which have shown that quercetin protects human lym-
phocytes against oxidative DNA damage in vitro (Fabi-
ani et al., 2001).
It should be noted that etoposide induced extensive 
oxidative DNA damage, which is consistent with the re-
sults obtained in previous studies (Papież, 2013). 
Previous in vitro studies have also shown that querce-
tin inhibits the formation of etoposide phenoxyl radicals 
in human neutrophils and may protect the cells from 
apoptosis induced by etoposide at a concentration of 
25 µM (Kapiszewska et al., 2007). Hovewer, the present 
results suggest that pre-treatment with quercetin protects 
neutrophil precursors and other cells of the myeloid 
lineage against myelosuppressive effect of etoposide. 
Quercetin can thus protect neutrophils at various stag-
es of their maturation. This protective effect was most 
marked within erythroid precursors and granulocytic 
lines, and restored the correct ratio of mature neutro-
phils to their precursors. It should be mentioned that in 
vitro studies have proven the protective effect of querce-
tin  at a concentration of 1 μM against genotoxic action 
of etoposide in neutrophils (Kapiszewska et al., 2007). 
However, the quercetin concentration in blood plasma 
of rats treated with 80 mg/kg b.w. of this flavonoid is 
2.7 µM, (Papież et al., 2008).
Another studies has shown that quercetin administra-
tion to mice at a dosage of 50 mg/kg led to a decrease 
Figure 1. The extent of oxidative DNA damage induced by 
etoposide and/or querectin in LT-12 cells. 
The cells were incubated for 1 and 24 hours with qurecetin and/
or etoposide. The oxidative DNA damage was measured in LT-12 
cells by using comet assay. C — control, Q — quercetin, E — eto-
poside. p*<0.05 vs. control, p**<0.01 vs. control, p#<0.05 vs. eto-
poside, p##<0.01 vs. etoposide. Data are presented as the mean 
± standard error of the mean, p<0.05.
Figure 2. The extent of oxidative DNA damage induced by 
etoposide and/or querectin in rat bone marrow cells. 
The rats were given quercetin at a dose of 100 mg/kg b.w. by 
gavage for 14 days. Etoposide was administered i.p. at a dose of 
50 mg/kg b.w. for 3 consecutive days. The last group of experi-
mental rats was administered with quercetin for 11 days followed 
by the coadministration of etoposide for the last 3 days of the 
experiment. Control group of rats was given solvent for exam-
ined compounds. The oxidative DNA damage was measured in 
the bone marrow cells by using comet assay. C — control, Q — 
quercetin, E — etoposide. p###<0.001 vs. control, p***<0.001 vs. 
etoposide. Data are presented as the mean ± standard error of the 
mean, p<0.05.
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in the amount of chromosomal aberrations induced by 
methotrexate in bone marrow cells and diminished the 
number of cells with methotrexate-induced aberrations. 
In that study, quercetin also increased the mitotic index 
inhibited by methotrexate administration (Sekeroğlu & 
Sekeroğlu, 2012). Other research has also shown that 
quercetin administered subcutaneously protected the 
bone marrow cells of rats against DNA double-strand 
breaks induced by etoposide (Kapiszewska et al., 2007). 
Similar results have been obtained in mice treated with 
topotecan, in which quercetin protected bone marrow 
cells against the geno- and cytotoxic action of this drug, 
while simultaneously raising the level of glutathione and 
reducing MDA levels in comparison to the cytostatic 
alone (Bakheet, 2011). 
The results of the present study indicate that querce-
tin exerts an antioxidant rather than prooxidant effect, 
despite its potential ability to create toxic conjugates 
with -SH groups in vitro (Brisdelli et al., 2006). Querce-
tin-thiol conjugates can reduce the levels of glutathione, 
and interfere with the function of proteins and enzymes, 
such as endoplasmatic reticulum calcium ATPase, form-
ing covalent complexes with them (Awad et al., 2002; 
Boots et al., 2007). The present results are in line with 
those other studies which have shown that quercetin 
acts as an antioxidant, protecting human chronic myeloid 
(K562) and acute lymphoblastic (HSB-2) leukemia cells 
from oxidative stress induced by tert-butylhydroperoxide 
(Brisdelli et al., 2006).
Etoposide phenoxyl radicals cause a decrease in glu-
tathione in cells (Kagan et al., 1999) which may lead to 
oxidation of the mitochondrial membrane phospholipids, 
loss of integrity of this membrane and the induction of 
apoptosis. Quercetin, as an antioxidant, can scavenge 
etoposide phenoxyl radicals, protecting normal bone 
marrow cells of rats against apoptotic death induced by 
oxidative stress. Quercetin may also prevent the conse-
quences of oxidative damage to DNA, which are DNA 
strand breaks leading to apoptosis or mutation (Sallmyr 
et al., 2008). Quercetin could also protect myeloid cells 
against the carcinogenic effect of etoposide by reducing 
the level of strong mutagen 8-oxo-dG induced by this 
cytostatic drug. Further studies on the mechanism of 
quercetin action may be helpful in modifying the effect 
of etoposide treatment in normal bone marrow cells. 
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